Valuation : CEL-SCI Corporation

Market Cap 2.67Cr 2.3Cr 2.17Cr 1.98Cr 3.69Cr 255.61Cr 3.73Cr 26Cr 9.94Cr 129.65Cr 10Cr 9.82Cr 411.8Cr P/E 2026 *
-0.5x
P/E 2027 * -0.24x
Enterprise Value 2.12Cr 1.82Cr 1.72Cr 1.57Cr 2.93Cr 202.51Cr 2.95Cr 20Cr 7.88Cr 102.72Cr 7.95Cr 7.78Cr 326.25Cr EV / Sales 2026 *
-
EV / Sales 2027 * 3.58x
Free-Float
93.16%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 67 01/01/1995
Director of Finance/CFO 75 13/11/2024
Chief Tech/Sci/R&D Officer - 01/05/2024
Director TitleAgeSince
Director/Board Member 67 01/01/1995
Director/Board Member 73 22/06/2015
Chairman 69 08/07/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.36%-14.33% - - 2.67Cr
-0.25%-1.36%+44.08%+102.76% 6.82TCr
-0.09%-4.19%+30.76%+74.13% 6.22TCr
-1.18%+0.47%-12.78%+384.69% 2.78TCr
-1.60%-5.04%+29.72%+9.37% 2.49TCr
-1.76%-6.30%-4.55%-19.75% 2.42TCr
-0.41%-3.93%+14.19%-19.75% 1.94TCr
-1.86%-2.22%+202.03%+353.89% 1.73TCr
-2.02%-5.27%-5.62%+493.60% 1.45TCr
-1.54%-2.88%+52.33%+159.75% 1.42TCr
Average -1.13%-3.30%+38.91%+170.96% 3.03TCr
Weighted average by Cap. -0.83%-3.10%+35.30%+136.49%

Financials

2026 *2027 *
Net sales - 59.72L 51.36L 48.46L 44.15L 82.52L 57Cr 83.27L 5.77Cr 2.22Cr 29Cr 2.24Cr 2.19Cr 92Cr
Net income -2.51Cr -2.16Cr -2.04Cr -1.85Cr -3.47Cr -239.82Cr -3.5Cr -24Cr -9.33Cr -121.64Cr -9.42Cr -9.21Cr -386.37Cr -2.95Cr -2.54Cr -2.39Cr -2.18Cr -4.08Cr -282.18Cr -4.12Cr -29Cr -11Cr -143.12Cr -11Cr -11Cr -454.6Cr
Net Debt -55.54L -47.76L -45.07L -41.06L -76.75L -53Cr -77.44L -5.37Cr -2.07Cr -27Cr -2.09Cr -2.04Cr -86Cr -53.39L -45.92L -43.32L -39.47L -73.78L -51Cr -74.45L -5.16Cr -1.99Cr -26Cr -2Cr -1.96Cr -82Cr
Logo CEL-SCI Corporation
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!